$MCET MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies.
MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.
DPLS Security Details Share Structure Market Value1...........$56,403,908 a/o Feb 02, 2021 Authorized Shares..20,000,000,000 a/o Jan 28, 2021 Outstanding Shares..4,338,762,156 a/o Jan 28, 2021 Restricted...............31,894,998 a/o Jan 28, 2021 Unrestricted..........4,306,867,158 a/o Jan 28, 2021 Held at DTC...............Not Available Float.....................Not Available Par Value 0.01
Market Data 
Markets 
AI
